Short description:
Novel central nervous system-targeted assets
Drug notes:
LP659 Clin0 neurological diseases; LP143 RD undisclosed; nelotanserin RD undisclosed
Long description:
Longboard Pharmaceuticals is developing therapies for patients with neurological and rare diseases. Many important categories of drugs target G protein-coupled receptors (GPCRs) that regulate various biological processes within cells. Longboard was conceived to advance a portfolio of drugs that are highly selective for GPCs using their expertise in drug development and optimization. Their lead program, LP352, is an oral small molecule that binds the GPCR 5-HT2C, which Longboard is testing as a treatment of seizures associated with patients with Developmental and Epileptic Encephalopathy syndromes.
Jobs:
Europe, Site Engagement and Enrollment Lead European Union|12 days ago
APAC, Site Engagement and Enrollment Lead APAC|12 days ago
North America, Site Engagement and Enrollment Lead... La Jolla, CA|14 days ago
Quality Systems Senior Manager La Jolla, CA|29 days ago
Associate Field Scientific Director - Australia Australia|53 days ago
Associate Field Scientific Director - Europe European Union|53 days ago
Global Clinical Trial Lead United States|70 days ago
Director, Data Management La Jolla, California, Stati Uniti d'America|75 days ago
Senior Manager/Associate Director, Drug Safety Ope... Stati Uniti d'America|87 days ago
Clinical Research Associate (CRA, In-House) La Jolla, CA|100+ days ago